<code id='D483CEE909'></code><style id='D483CEE909'></style>
    • <acronym id='D483CEE909'></acronym>
      <center id='D483CEE909'><center id='D483CEE909'><tfoot id='D483CEE909'></tfoot></center><abbr id='D483CEE909'><dir id='D483CEE909'><tfoot id='D483CEE909'></tfoot><noframes id='D483CEE909'>

    • <optgroup id='D483CEE909'><strike id='D483CEE909'><sup id='D483CEE909'></sup></strike><code id='D483CEE909'></code></optgroup>
        1. <b id='D483CEE909'><label id='D483CEE909'><select id='D483CEE909'><dt id='D483CEE909'><span id='D483CEE909'></span></dt></select></label></b><u id='D483CEE909'></u>
          <i id='D483CEE909'><strike id='D483CEE909'><tt id='D483CEE909'><pre id='D483CEE909'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:knowledge    Page View:478
          Glaxo Smith Kline
          Akira Suemori/AP

          A few years ago, Vijay Pande, then a professor at Stanford who was using computer science to understand biology, was deciding whether to leave full-time academic work to become a venture capitalist. He turned to Andrew Ng, another Stanford professor who had joined Google Brain and later the Chinese search firm Baidu.

          “The things that we dreamed about five or 10 years ago were happening now,” Pande recalled Ng telling him. “The question was, do you want to be a part of it? Or do you want to write another paper?”

          advertisement

          Pande decided to become a venture capitalist. The result, he told an audience at a STAT event in San Francisco last week, is that, whereas he managed about $1 million to $2 million in research as a top academic, he now works at the fabled Silicon Valley firm Andreessen Horowitz, which invests $100 million a year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc
          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

          InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          The FDA must approve intranasal treatments for anaphylaxis

          AdobeMysonThomashascarriedaroundaneedlesinceheenteredkindergartenattheageof5.Thatwasabigresponsibili